Individualized PET/CT-based bone marrow dosimetry may be a more accurate tool than plasma-based dosimetry in the delivery of therapeutic radiolabeled antibodies in cancer patients, according to a study published in the Journal of Nuclear Medicine, in some cases allowing for higher doses of the therapeutic agent. The researchers used two 124I-labeled antibodies, cG250 and huA33.

Related Summaries